The price of roflumilast can vary significantly based on several factors, including the specific formulation, dosage, pharmacy, insurance coverage, and availability of discount programs.
How much does roflumilast typically cost without insurance?
Without insurance, a prescription for roflumilast can range from approximately $300 to over $700 for a 30-day supply. This price reflects the cost of the medication itself before any potential discounts or patient assistance programs are applied.
Are there ways to lower the cost of roflumilast?
Several options may help reduce the out-of-pocket expense for roflumilast. Prescription discount cards and coupons, often available through pharmaceutical company websites or third-party discount providers, can offer savings. Some manufacturers also provide patient assistance programs for eligible individuals who lack adequate insurance coverage. Checking with your pharmacy or the drug manufacturer's website can provide details on available savings opportunities.
How does insurance affect roflumilast pricing?
Insurance coverage plays a crucial role in determining the final cost of roflumilast. Co-pays, deductibles, and the specific formulary tier assigned to roflumilast by an insurance plan will influence the patient's responsibility. Some insurance plans may require prior authorization before covering the medication.
What is roflumilast used for?
Roflumilast is a medication prescribed to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis [1]. It works by inhibiting an enzyme called phosphodiesterase 4 (PDE4), which helps to reduce inflammation in the lungs [2].
When does the patent for roflumilast expire?
Information on patent expiration dates for medications like roflumilast is often tracked by specialized services. According to DrugPatentWatch.com, the patent landscape for roflumilast may involve multiple patents with varying expiration timelines [3]. For specific and up-to-date patent expiry information, consulting resources like DrugPatentWatch.com is recommended.
What other drugs are similar to roflumilast?
Roflumilast belongs to a class of drugs called phosphodiesterase 4 (PDE4) inhibitors. Other medications in this class, or those used for similar conditions, might include inhaled corticosteroids, long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs), though they work through different mechanisms.
Who manufactures roflumilast?
Roflumilast is marketed under the brand name Daliresp by its developer, AstraZeneca [1].
What are the potential side effects of roflumilast?
Common side effects associated with roflumilast can include diarrhea, nausea, headache, and weight loss [1]. Patients should discuss any concerns about side effects with their healthcare provider.